Bethanie Wilkinson

Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine

Cheryl Keech, Gary Albert, Iksung Cho et al. · New England Journal of Medicine · 2020 · 1.2K citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17

Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis

Ronald van Vollenhoven, Roy Fleischmann, Stanley Cohen et al. · New England Journal of Medicine · 2012 · 939 citations · Full text

Medicine, Immunology, Pharmacology +13

Tofacitinib versus Methotrexate in Rheumatoid Arthritis

Eun Bong Lee, Roy Fleischmann, Stephen Hall et al. · New England Journal of Medicine · 2014 · 774 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double‐blind, placebo‐controlled phase IIa trial of three dosage levels of CP‐690,550 versus placebo

Joel M. Kremer, Bradley J. Bloom, Ferdinand C. Breedveld et al. · Arthritis & Rheumatism · 2009 · 544 citations

Medicine, Pharmacology, Pharmacotherapy +14

Phase IIb dose‐ranging study of the oral JAK inhibitor tofacitinib (CP‐690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease‐modifying antirheumatic drugs

Roy Fleischmann, Maurizio Cutolo, Mark C. Genovese et al. · Arthritis & Rheumatism · 2011 · 379 citations

Medicine, Pharmacology, Pharmacotherapy +15